Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA

Maura K. Lash, Ned H. Latham, Pui Ying Chan,Mary M. K. Foote,Elizabeth A. Garcia,Matthew F. Silverstein,Marcia Wong, Mark Alexander, Karen A. Alroy, Lovedeep Bajaj, Kuan Chen, James Steele Howard,Lucretia E. Jones,Ellen H. Lee, Julian L. Watkins,Tristan D. Mcpherson

EMERGING INFECTIOUS DISEASES（2023）

引用 0|浏览4

暂无评分

摘要

We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要